Abstract-Preliminary studies show that intranasal (i.n.) administration of BCG in mice induces M1 activation of alveolar macrophages (M∅) that increase TNF-α production and cyclooxygenase-2 (COX-2) expression but reduce constitutive peroxisome proliferator-activated receptor gamma (PPARγ) expression. However, COX-2 is catalytically inactive for prostaglandin E 2 release, unlike COX-2 that is active in M1 activation in vitro by BCG. In this study, we determined the role of PPARγ for BCG-induced M1 activation in vivo and in vitro. We found that treatment of mice with GW9662, a PPARγ antagonist, prior to i.n. BCG, partially restored PPARγ expression, and decreased TNF-α production and COX-2 expression. But COX-2 was still inactive. The decreased effects on TNF-α and COX-2 were also observed when alveolar M∅ were treated in vitro with GW9662/BCG, but COX-2 was still active. Our results indicate that PPARγ upregulates M1 activation of alveolar M∅, but inactive COX-2 formation is independent of PPARγ in mycobacterial pulmonary inflammation.
INTRODUCTION
Inducible cyclooxygenase-2 (COX-2), a marker for classically (M1) activated macrophages (M∅), is central to increased biosynthesis of immunoregulatory prostaglandins including prostaglandin E 2 (PGE 2 ) [1] [2] [3] . When normal alveolar M∅ are activated in vitro with heat-killed Mycobacterium bovis BCG, a human tuberculosis vaccine and Th1 adjuvant, COX-2 is induced; this COX-2 is subcellularly associated with the nuclear envelope (NE) and catalytically active [4] . In sharp contrast, intranasal (i.n.) BCG administration induces only catalytically inactive and NE-dissociated COX-2 (and COX-1) that is accumulated and aggregated in the endoplasmic reticulum (ER) in alveolar M∅ [4] . Although PGE synthase, converting PGH 2 to PGE 2 , appears to be active [3] , these COX-2 + M∅ release no PGE 2 [4] . We use the designations active or inactive COX-2 interchangeably with NE associated or dissociated, respectively [4] [5] [6] , but the exact in vivo mechanism regulating alveolar M∅ activation in mycobacterial pulmonary inflammation is still unclear.
Mucosal PGE 2 downregulates innate and Th1-mediated immune responses, such as mucosal granuloma formation and bactericidal M1 activation [7] [8] [9] [10] . Simultaneously, PGE 2 upregulates alternatively activated M∅ (M2), Th2 immune responses and antibody production [1, [11] [12] [13] , including mucosal anti-mycobacterial IgA antibodies [14] . It is also reported that PGE 2 reduces necrotic death of bactericidal M∅, thereby inhibiting bacterial replication [15] . Therefore, alveolar M∅, which are activated by i.n. BCG and release no PGE 2 , are expected to promote Th1-mediated mucosal protection against pulmonary M. tuberculosis challenges [16] , as well as the granuloma formation [17] .
It should be noticed that the kinetics of inactive COX-2 + M∅ formation is dependent on tissues and routes of BCG administration. To induce inactive COX-2 formation in alveolar M∅, intranasal route of BCG administration is required. Intranasal administration of BCG induces NEdissociated COX-2 up to 28 days, whereas intraperitoneal administration of BCG does not induce COX-2 in alveolar M∅ and only transiently induces NE-dissociated COX-2 in peritoneal and splenic M∅. Therefore, intraperitoneal administration of BCG is inappropriate for the induction of pulmonary inflammation [1, 3, 5, 6] . Alveolar M∅ from humans and mice constitutively express relatively high levels of peroxisome proliferatoractivated receptor gamma (PPARγ) at normal steady state [18] [19] [20] . Intranasal BCG administration reduced PPARγ expression (Preliminary study). PPARγ enhances protein degradation in the ER by inducing an ER stress response [21, 22] , which could theoretically explain the accumulation of inactive COX-2 in the ER in alveolar M∅ activated by BCG in vivo. Furthermore, acting in an anti-inflammatory role, PPARγ antagonizes inflammatory transcription factors (e.g., NF-κB and activator protein-1 [AP-1]) [23] . Therefore, deletion of the PPARγ gene in murine alveolar M∅ results in persistent production of interferon-γ (IFN-γ) and expression of inducible nitric oxide synthase (iNOS) [24] . On the other hand, PPARγ agonist treatments in vitro of several M∅ including thioglycollate-elicited peritoneal M∅, bone marrow-derived M∅, and monocyte-derived M∅ and J774 M∅ result in inhibition of COX-2 and iNOS expression and M1 cytokine production [23, 25, 26] . Consistent with this observation, an irreversible antagonist of PPARγ, GW9662, enhanced COX-2 expression, and PGE 2 release in vitro by LPS-stimulated J774.2 M∅, indicating that PPARγ downregulates active COX-2 expression [25] . Based on these studies, it has been hypothesized that PPARγ downregulates COX-2 expression in our alveolar M∅.
The literature, however, does not always support the hypothesis that PPARγ downregulates COX-2 activity in M∅. Unlike LPS, PPARγ agonist NSAID diclofenac increases COX-2 expression and PGE 2 release in J744.2 M∅ cultures [25] . GW9662 inhibits BCG-induced PGE 2 release by peritoneal M∅ in vitro [27] . In the present study, our goals were to determine using GW9662 whether PPARγ downregulates M1 activation and COX-2 expression and whether PPARγ contributes to the accumulation of inactive COX-2 when alveolar M∅ are activated by i.n. BCG. The data presented here have documented the role of PPARγ on BCG-induced M1 activation with COX-2 expression in alveolar M∅ in vivo. The in vivo results have also been compared with those from in vitro alveolar M∅ activation with BCG.
MATERIALS AND METHODS

Mice
Non-pregnant female C57Bl/6 mice, 8-10 weeks old, were obtained from The Jackson Laboratory (Bar Harbor, ME). Experimental protocols employed in this study were approved by the IACUC at Florida Atlantic University.
Administration of BCG and GW9662
M. bovis BCG Tokyo 172 strain (Japan BCG Laboratory, Tokyo, Japan) was prepared [4] . Five, 50, or 500 μg of BCG in 0.05 ml saline was administered i.n. to groups of 3-6 mice, as described [4] . As a control, mice were given i.n. doses of 0.05 ml saline. To evaluate the role of the PPARγ pathway, GW9662 (1 mg/kg in saline; Cayman Chemical, Ann Arbor, MI) was given twice intraperitoneally 50 min followed by i.n. 20 min before i.n. BCG administration. The schedule of GW9662 treatment was chosen based on previous studies [28, 29] . Alveolar M∅ were isolated 24 h after the BCG administration.
M∅ Preparations
To obtain alveolar M∅ from mice, bronchoalveolar lavage (BAL) cells were obtained [4] . Total cell counts were determined with a Coulter counter (Model Z1; Beckman Coulter, Hialeah, FL).
To enrich plastic-adherent M∅, BAL cells at 10 6 cells/ml in RPMI 1640 containing 5 % heatinactivated fetal bovine serum (FBS), 100 units/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin B were incubated in culture dishes (Falcon, Oxnard, CA) for 1 h at 37°C. BAL M∅ and other inflammatory cells were enumerated by differential counts following cytospin preparations and staining with Diff-Quik (Baxter Healthcare, Miami, FL). Adherent BAL cell differentials from all animals used in experiments revealed >90 % M∅. In some experiments, adherent M∅ were further cultured with 20 or 100 μg/ml BCG for additional 24 h. GW9662 (10 μM) [30] was added 30 min before BCG addition.
Western Blot
Washed M∅ were resuspended in lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.1 % SDS, 4 mM EDTA, 1 % NP-40, 10 mM NaF, 2 mM Na 3 VO 4 , 0.1 % sodium deoxycholate, and 1:500 protease inhibitor cocktail [P8340; Sigma Aldrich]). After 10 min on ice, debris was eliminated by centrifugation (10 min at 10,000×g). Protein concentration in the lysate was measured with a bicinchoninic acid assay (Pierce, Rockford, IL). Equal amounts of protein from each sample were separated by SDS-PAGE and then transferred to a PVDF membrane (Millipore, Bedford, MA). The membrane was blocked with 7. 
Subcellular Localization of COX-1 and COX-2 by Confocal Microscopy
To identify the NE-localization of COX-2 (and COX-1), M∅ were fixed in 4 % paraformaldehyde in PBS, pH 7.5, for 20 min, permeabilized with 0.1 % Triton X-100 in PBS for 7 min, and incubated in blocking buffer (PBS with 10 % FBS) overnight at 4°C prior to incubation overnight at 4°C with anti-COX-2 (1:500) or anti-COX-1 antibody (1:500) in blocking buffer. Subsequently, cells were washed with PBS three times and incubated for 1 h at 22°C
with Alexa Fluor 488 goat anti-rabbit IgG (1:500; Invitrogen, Carlsbad, CA) and 10 μg/ml propidium iodide (PI; Sigma Aldrich) for detection of nuclei and BCG [6] . After washing three times, cells were examined with a laser scanning confocal microscope (LSM700, ZEISS, Thornwood, NY) with ZEN Software.
Measurement of PGE 2 and TNF-α Concentrations
Levels of PGE 2 from the cell cultures and TNF-α in supernatants from the BAL and cell cultures were measured by ELISA, as previously described [4] .
Statistical Analysis
The statistical significance for differences between values was determined by one way analysis of variance followed by the Scheffé post hoc test for multiple comparisons. All statistical analyses were performed with StatView Version 5.0 (SAS Institute Inc., Cary, NC). Results are expressed as mean±SEM. p<0.05 is considered statistically significant.
RESULTS
PPARγ Mediates COX-2 Expression in Alveolar M∅ When Activated by I.N. BCG
Immunoreactive PPARγ consisting of 53-kDa PPARγ1 and 57-kDa PPARγ2 as well as a relatively low level of COX-1 were present in alveolar M∅ isolated from saline-treated control mice (Fig. 1) . PPARγ2 has not been previously reported in alveolar M∅; it is thought to be selectively expressed in adipose and to induce adipose differentiation [31, 32] . BCG reduced both PPARγ1 and PPARγ2 levels, increased COX-1expression, and induced COX-2 expression in a dose-dependent manner (Fig. 1) .
To determine whether PPARγ participates in these M∅ responses, mice were treated with GW9662 prior to i.n. BCG administration. GW9662 is an irreversible PPARγ antagonist that covalently modifies a cysteine residue in the ligand binding site of PPARγ, resulting in the loss of ligand binding [33] . GW9662 is highly selective for the inhibition of PPARγ, since 10-and 600-fold more are required for the inhibition of PPARα and PPARδ, respectively [33] . As shown in Fig. 2 , GW9662 alone had no effect on the constitutive levels of COX-1 and induced no COX-2, but slightly reduced PPARγ. GW9662/BCG treatment reduced the BCG-increased COX-1 and COX-2 levels. PPARγ expression was reduced by BCG alone to 3 % of control, and recovered by GW9662/BCG to 41 % of control (Fig. 2) . These results indicate that BCG suppression of PPARγ was associated with enhanced expression of COX-1 and COX-2.
As reported previously [4] , over 95 % of alveolar M∅ isolated from mice given i.n. 500 μg dose BCG exhibit NE-dissociated COX-1 and COX-2, detected by immunofluorescent staining and confocal microscopy ( Fig. 3) . Despite less expression of COX-2 in M∅ treated at 5 and 50 μg doses than those at 500 μg BCG dose, over 90 % of these COX-2 + M∅ showed NE-dissociated forms (data not shown). As shown in Fig. 3 , more than 95 % of COX-1 + and COX-2 + alveolar M∅ in the group of GW9662/BCG still showed NE-dissociated forms. Alveolar M∅ isolated from untreated and BCG-treated mice both release around 300 pg PGE 2 /10 6 cells [4] ; alveolar M∅ isolated from any of the four groups in this study released comparable ranges of PGE 2 (data not shown). Taken together, our results indicate that PPARγ enhances COX-2 expression but does not contribute to the subcellular localization of COX-2 in BCG-activated alveolar M∅.
GW9662 is known to reduce phagocytosis of apoptotic neutrophils by human monocyte-derived M∅ [34] . To confirm that the effects of PPARγ are not being mediated by impairment of BCG phagocytosis, we examined the percent of cells that contained intracellular BCG. We found that in both the BCG and the GW9662/BCG treatment groups, 95 % M∅ phagocytosed BCG (data not shown). We conclude that PPARγ had no effect on phagocytosis of BCG.
PPARγ Mediates BCG-Induced COX-2 Expression in Alveolar M∅ When Activated In Vitro
Incubation of alveolar M∅ with BCG in vitro resulted in slightly but significantly reduced PPARγ (PPARγ1) levels along with dose-dependent increases in levels of COX-2 (Fig. 4) ; all COX-2 + M∅ showed NEassociated COX-2 (data not shown). Interestingly, expression of PPARγ2 in alveolar M∅ was lost after 24 h in vitro without BCG (Fig. 4) , but not after 1 h incubation ( Figs. 1 and 2 ). As we found previously [4] , levels of COX-1 were not increased by BCG treatment in vitro (Fig. 4) .
Next, we determined the role of PPARγ in BCGinduced NE-associated COX-2 expression in vitro. The reduction of PPARγ (γ1) following exposure to BCG was not prevented by GW9662 (Fig. 5a) . Moreover, COX-1 in alveolar M∅ was not induced by BCG or GW9662/BCG. In contrast, BCG-induced COX-2 expression and PGE 2 release were both significantly reduced by GW9662 (Fig. 5a-c) . However, GW9662/BCG did not impair the localization of active COX-2 in the NE since over 99 % of COX-2 + M∅ showed NE-localization (Fig. 5d) . Taken together, the induction of COX-2 expression and increased PGE 2 release by BCG are dependent on PPARγ signaling; PPARγ does not alter the localization of COX-2 in vitro.
PPARγ Upregulates BCG-Induced TNF-α Production In Vivo and In Vitro
Animals treated intranasally with BCG alone had significant increase of TNF-α production in bronchoalveolar lavage (BAL) than that in saline-treated controls (Fig. 6a) . This increase was completely reversed by GW9662/BCG together. An inhibitory effect on TNF-α production was also detected in alveolar M∅ cultures with BCG and GW9662 (Fig. 6b) . The results indicate that PPARγ enhances TNF-α production, another M1 phenotype.
DISCUSSION
Using GW9662, a highly selective and irreversible PPARγ antagonist [33] , we have shown for the first time that PPARγ upregulates M1 activation and COX-2 expression in alveolar M∅ when activated by BCG in vivo (Fig. 2 ) or in vitro (Fig. 5) . However, PPARγ does not contribute to the formation of NE-dissociated/inactive COX-2 (Fig. 3) or the NE-associated/active COX-2 (Fig. 5) , respectively. Table 1 summarizes the effects of GW9662 on the expression of COX-2 and PGE 2 release. Malur et al. [24] demonstrated that lack of PPARγ in alveolar M∅ in PPARγ −/− mice disrupts lung homeostasis and results in an M1-like inflammatory response. Taken together, these results suggest that constitutive PPARγ downregulates M1 activation in the normal steady state, whereas PPARγ upregulates M1 activation in mycobacterial pulmonary inflammation.
A provocative finding is that when alveolar M∅ are activated by BCG, PPARγ expression is reduced (Fig. 1) in association with induction of TNF-α, COX-1 and COX-2. The literature suggests that the PPARγ deficiency is comparable to that observed in sarcoidosis, pulmonary alveolar proteinosis, and asthma in humans, as well as in several animal models of lung inflammation [35] [36] [37] [38] [39] [40] . Furthermore, activation of PPARγ by IFN-γ, thiazolidinediones, or endogenous ligands in adipocytes results in PPARγ degradation mediated by ubiquitinproteasome and TNF-α-activated caspase-1 [31, 32] . Thus, a GW9662-sensitive mechanism for reducing PPARγ levels could include endogenous and exogenous PPARγ agonists generated by BCG treatments. The PPARγ pathway has been reported to mediate bovine serum albumin-induced ER stress in renal proximal tubule cells [22] and 15d-PGJ 2 -induced ER stress, which attenuates IL-1 and IFN-γ signaling in pancreatic β-cells [21] . COX-2 can be degraded in the ER via the ER-associated degradation pathway in response to an ER stress [41, 42] . It is possible, therefore, that the accumulation of inactive COX-2 formation in response to i.n. BCG is mediated by an ER stress, but independent of PPARγ signaling.
In addition to COX-2 and PPARγ, COX-1 expression by alveolar M∅ is distinct between in vivo and in vitro BCG treatments; COX-1 is increased by in vivo, but not in vitro, treatment with BCG ( Figs. 1 and 4) . COX-1 is detected by western blot with 5 μg or less protein/lane when samples were prepared from normal peritoneal M∅; the levels are almost unchanged among the control and treatments with BCG in vivo and in vitro [4, 5] . The differential expression of COX-1 between in vivo and in vitro conditions, therefore, is somewhat more notable in alveolar M∅ than peritoneal M∅. Our results clearly show that PPARγ upregulates COX-1 expression in vivo (Fig. 2) , although it is NE-dissociated (Fig. 3) . Additional tissue-dependent cells and humoral factors, lacking in vitro M∅ cultures, would contribute to the in vivo M∅ activation. Identifying such limiting cells/factors for these phenotypes remains to be studied.
Almeida et al. [27] demonstrated that when peritoneal M∅ are treated in vitro with BCG, increased PPARγ enhances PGE 2 release. In our preliminary study, we found that GW9662 inhibited PGE 2 release but COX-1 and COX-2 levels were unchanged when normal peritoneal M∅ were treated in vitro with GW9662 and BCG (data not shown). These COX-1 and COX-2 were all NE-associated (data not shown). Therefore, it is possible that PPARγ upregulates phospholipase A 2 and/or PGE synthase or downregulates 15-prostaglandin dehydrogenase (which converts PGE 2 to DHK-PGE 2 implies that PPARγ has multiple and tissue-dependent roles for the regulation of M∅ PGE 2 biosynthesis. It is unlikely that over-expression of COX-2 (and COX-1) at relatively higher doses of BCG in vivo would result in NE-dissociation. Our results indicate that (a) COX-2 levels are comparable between in vivo and in vitro BCG treatments (Figs. 1 and 4) , and (b) the expressions of COX-1 and COX-2 are reduced by in vivo GW9662 plus BCG, but still NE-dissociated forms (Figs. 2 and 3) . However, factors regulating the COX-2 phenotypes and distinction between in vivo and in vitro conditions [4] [5] [6] are still unknown. The difference between M∅ exposed to BCG in vivo and those exposed in vitro would be reduction/oxidation (redox) states [43, 44] , monocyteinfiltrated M∅ [45] , and additional cell populations such as mast cells that are activated by BCG in vivo and modify the M∅ activation [46] . Prior to the present study, we conducted studies to test if the above factors significantly contribute to the regulation of COX-2 NE-localization. In the preliminary studies, we used (a) mice deficient in methionine sulfoxide reductase A, an enzyme protecting hosts from oxidative damages [47] , (b) mice deficient in Flt-1-tyrosine kinase, an enzyme regulating monocyte infiltration [48] , (c) mice deficient in CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells), a receptor of PGD 2 derived from activated mast cells [49] . We found, however, that alveolar M∅ isolated from these animals still showed NE-dissociated COX-2 when activated in vivo with BCG and NEassociated COX-2 when activated in vitro (data not shown).
We conclude that PPARγ in alveolar M∅ enhances M1 activation including COX-2 expression, but the subcellular localization of COX-2 is regulated by a PPARγ-independent pathway in mycobacterial pulmonary inflammation. Antagonism of PPARγ may contribute to the suppression of excessive mucosal M1 activation without changing mucosal PGE 2 level. Finally, further studies are necessary to elucidate the mechanisms regulating NE-dissociated/inactive COX-2 formation.
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